The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis

Introduction: Immunoglobulin A vasculitis (IgAV) is an inflammatory disease mediated by B cells. Nuclear factor kappa B (NF-kB) is essential for B-cell development and maturation and plays a key role in autoimmunity and inflammation. In particular, the NF-kB canonical activation pathway genes NFKB1...

Descripción completa

Detalles Bibliográficos
Autores: Batista Liz, Joao Carlos, Sebastián Mora Gil, María, Renuncio García, Mónica, Leonardo Cabello, María Teresa, Peñalba Citores, Ana Cristina, Gabriel Odonnell, Ligia, Sánchez, Rafael Gálvez, Martín Penagos, Luis, Narvaez, Javier, Sevilla Pérez, Belén, Ríos Fernández, Raquel, Callejas Rubio, José Luis, Caminal Montero, Luis, Collado, Paz, Pérez Venegas, José Javier, Rodríguez Valls, María José, De Árgila, Diego, Quiroga Colina, Patricia, Vicente Rabaneda, Esther Francisca, Ocejo-Vinyals, Javier Gonzalo
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/39101
Acceso en línea:https://hdl.handle.net/10902/39101
Access Level:acceso abierto
Palabra clave:Biomarkers
Immunoglobulin A vasculitis (IgAV)
NF-kappa B (NF-kB)
NFKB1
NFKBIA
id ES_f8dbcd1a3848b47ecba01b4a250dcbb2
oai_identifier_str oai:repositorio.unican.es:10902/39101
network_acronym_str ES
network_name_str España
repository_id_str
spelling The role of NFKB1 and NFKBIA in immunoglobulin A vasculitisBatista Liz, Joao CarlosSebastián Mora Gil, MaríaRenuncio García, MónicaLeonardo Cabello, María TeresaPeñalba Citores, Ana CristinaGabriel Odonnell, LigiaSánchez, Rafael GálvezMartín Penagos, LuisNarvaez, JavierSevilla Pérez, BelénRíos Fernández, RaquelCallejas Rubio, José LuisCaminal Montero, LuisCollado, PazPérez Venegas, José JavierRodríguez Valls, María JoséDe Árgila, DiegoQuiroga Colina, PatriciaVicente Rabaneda, Esther FranciscaOcejo-Vinyals, Javier GonzaloBiomarkersImmunoglobulin A vasculitis (IgAV)NF-kappa B (NF-kB)NFKB1NFKBIAIntroduction: Immunoglobulin A vasculitis (IgAV) is an inflammatory disease mediated by B cells. Nuclear factor kappa B (NF-kB) is essential for B-cell development and maturation and plays a key role in autoimmunity and inflammation. In particular, the NF-kB canonical activation pathway genes NFKB1 (encoding NF-kB1) and NFKBIA (encoding NF-kB inhibitor alpha) have been identified as risk loci for several immune-mediated diseases, but their role in IgAV remains unclear. This study aimed to determine whether NFKB1 and NFKBIA represent novel genetic risk factors for IgAV pathogenesis. Methods: The NFKB1 promoter variant −94 ins/del ATTG (rs28362491), six tag NFKB1 polymorphisms (rs77830930, rs1598856, rs7340881, rs4648055, rs4648090, and rs230547), and seven tag NFKBIA variants (rs3138055, rs696, rs1022714, rs2233419, rs2233415, rs1050851, and rs1957106) were genotyped in 343 Caucasian IgAV patients and 764 healthy, ethnically matched controls using TaqMan probes. Patients were stratified according to age at disease onset and the presence or absence of renal, articular, and gastrointestinal manifestations. Genotype, allele, and haplotype frequencies were compared between patients and controls, as well as across clinical subgroups. Results: No statistically significant differences were found in genotype or allele frequencies of NFKB1 or NFKBIA between IgAV patients and healthy controls. Likewise, haplotype frequencies of both genes were similar across groups. No associations were observed when patients were stratified by clinical features, including renal involvement, age at onset, or articular/gastrointestinal symptoms. Conclusion: Our findings do not support a major role for the NFKB1 or NFKBIA variants studied in IgAV susceptibility or severity. These results suggest that if NFkB signaling contributes to IgAV pathogenesis, it likely involves other biological mechanisms.The author(s) declare financial support was received for the research and/or publication of this article. This research was funded by European Union FEDER funds and “Fondo de Investigaciones Sanitarias” from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain), grant numbers PI21/00042 and PI24/00382. JCBL. is a recipient of a PFIS program fellowship from the ISCIII, cofunded by the European Social Fund (‘Investing in your future’), grant number FI22/00020. VP-C received funding from IDIVAL, grant numbers NVAL23/02 and INNVAL24/10. RL-M is a recipient of a Miguel Servet type II program fellowship from the ISCIII, cofunded by ESF (“Investing in your future”), grant number CPII21/00004.Frontiers Research FoundationUniversidad de Cantabria20252025-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/39101Frontiers in Immunology, 2025, 16, 1692908reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/391012026-06-02T12:39:31Z
dc.title.none.fl_str_mv The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
title The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
spellingShingle The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
Batista Liz, Joao Carlos
Biomarkers
Immunoglobulin A vasculitis (IgAV)
NF-kappa B (NF-kB)
NFKB1
NFKBIA
title_short The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
title_full The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
title_fullStr The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
title_full_unstemmed The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
title_sort The role of NFKB1 and NFKBIA in immunoglobulin A vasculitis
dc.creator.none.fl_str_mv Batista Liz, Joao Carlos
Sebastián Mora Gil, María
Renuncio García, Mónica
Leonardo Cabello, María Teresa
Peñalba Citores, Ana Cristina
Gabriel Odonnell, Ligia
Sánchez, Rafael Gálvez
Martín Penagos, Luis
Narvaez, Javier
Sevilla Pérez, Belén
Ríos Fernández, Raquel
Callejas Rubio, José Luis
Caminal Montero, Luis
Collado, Paz
Pérez Venegas, José Javier
Rodríguez Valls, María José
De Árgila, Diego
Quiroga Colina, Patricia
Vicente Rabaneda, Esther Francisca
Ocejo-Vinyals, Javier Gonzalo
author Batista Liz, Joao Carlos
author_facet Batista Liz, Joao Carlos
Sebastián Mora Gil, María
Renuncio García, Mónica
Leonardo Cabello, María Teresa
Peñalba Citores, Ana Cristina
Gabriel Odonnell, Ligia
Sánchez, Rafael Gálvez
Martín Penagos, Luis
Narvaez, Javier
Sevilla Pérez, Belén
Ríos Fernández, Raquel
Callejas Rubio, José Luis
Caminal Montero, Luis
Collado, Paz
Pérez Venegas, José Javier
Rodríguez Valls, María José
De Árgila, Diego
Quiroga Colina, Patricia
Vicente Rabaneda, Esther Francisca
Ocejo-Vinyals, Javier Gonzalo
author_role author
author2 Sebastián Mora Gil, María
Renuncio García, Mónica
Leonardo Cabello, María Teresa
Peñalba Citores, Ana Cristina
Gabriel Odonnell, Ligia
Sánchez, Rafael Gálvez
Martín Penagos, Luis
Narvaez, Javier
Sevilla Pérez, Belén
Ríos Fernández, Raquel
Callejas Rubio, José Luis
Caminal Montero, Luis
Collado, Paz
Pérez Venegas, José Javier
Rodríguez Valls, María José
De Árgila, Diego
Quiroga Colina, Patricia
Vicente Rabaneda, Esther Francisca
Ocejo-Vinyals, Javier Gonzalo
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad de Cantabria
dc.subject.none.fl_str_mv Biomarkers
Immunoglobulin A vasculitis (IgAV)
NF-kappa B (NF-kB)
NFKB1
NFKBIA
topic Biomarkers
Immunoglobulin A vasculitis (IgAV)
NF-kappa B (NF-kB)
NFKB1
NFKBIA
description Introduction: Immunoglobulin A vasculitis (IgAV) is an inflammatory disease mediated by B cells. Nuclear factor kappa B (NF-kB) is essential for B-cell development and maturation and plays a key role in autoimmunity and inflammation. In particular, the NF-kB canonical activation pathway genes NFKB1 (encoding NF-kB1) and NFKBIA (encoding NF-kB inhibitor alpha) have been identified as risk loci for several immune-mediated diseases, but their role in IgAV remains unclear. This study aimed to determine whether NFKB1 and NFKBIA represent novel genetic risk factors for IgAV pathogenesis. Methods: The NFKB1 promoter variant −94 ins/del ATTG (rs28362491), six tag NFKB1 polymorphisms (rs77830930, rs1598856, rs7340881, rs4648055, rs4648090, and rs230547), and seven tag NFKBIA variants (rs3138055, rs696, rs1022714, rs2233419, rs2233415, rs1050851, and rs1957106) were genotyped in 343 Caucasian IgAV patients and 764 healthy, ethnically matched controls using TaqMan probes. Patients were stratified according to age at disease onset and the presence or absence of renal, articular, and gastrointestinal manifestations. Genotype, allele, and haplotype frequencies were compared between patients and controls, as well as across clinical subgroups. Results: No statistically significant differences were found in genotype or allele frequencies of NFKB1 or NFKBIA between IgAV patients and healthy controls. Likewise, haplotype frequencies of both genes were similar across groups. No associations were observed when patients were stratified by clinical features, including renal involvement, age at onset, or articular/gastrointestinal symptoms. Conclusion: Our findings do not support a major role for the NFKB1 or NFKBIA variants studied in IgAV susceptibility or severity. These results suggest that if NFkB signaling contributes to IgAV pathogenesis, it likely involves other biological mechanisms.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
NA
http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10902/39101
url https://hdl.handle.net/10902/39101
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Frontiers Research Foundation
publisher.none.fl_str_mv Frontiers Research Foundation
dc.source.none.fl_str_mv Frontiers in Immunology, 2025, 16, 1692908
reponame:UCrea Repositorio Abierto de la Universidad de Cantabria
instname:Universidad de Cantabria (UC)
instname_str Universidad de Cantabria (UC)
reponame_str UCrea Repositorio Abierto de la Universidad de Cantabria
collection UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425041299472384
score 15,81155